Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency
about
Tumor suppressors: enhancers or suppressors of regeneration?Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardiumNeuroD1 mediates nicotine-induced migration and invasion via regulation of the nicotinic acetylcholine receptor subunits in a subset of neural and neuroendocrine carcinomas.Human stem cells for craniomaxillofacial reconstruction.Elimination of undifferentiated human embryonic stem cells by cardiac glycosides.Tumour resistance in induced pluripotent stem cells derived from naked mole-rats.Bioinformatic analysis of the four transcription factors used to induce pluripotent stem cells.Increased Arf/p53 activity in stem cells, aging and cancer.Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.Mitophagy-driven mitochondrial rejuvenation regulates stem cell fateNuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.Preclinical studies for induced pluripotent stem cell-based therapeuticsEpigenetic reprogramming, gene expression and in vitro development of porcine SCNT embryos are significantly improved by a histone deacetylase inhibitor--m-carboxycinnamic acid bishydroxamide (CBHA).Lineage conversion methodologies meet the reprogramming toolbox.SOX2 and cancer: current research and its implications in the clinicHumanized mouse models: Application to human diseases.The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.Low oxygen tension enhances the generation of lung progenitor cells from mouse embryonic and induced pluripotent stem cells.Ageing: Genetic rejuvenation of old muscle.Effects of Klf4 and c-Myc Knockdown on Pluripotency Maintenance in Porcine Induced Pluripotent Stem Cell.Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.New insights and clinical advancements in cellular oncology.
P2860
Q24618747-66E0F7BE-9042-41D3-9EFB-8EC90D804192Q28305306-FAB76FD4-2C60-47DF-9A2C-28BDAAE2F3A9Q33685667-17955771-2B5C-4DB7-A3A6-E9CA32167FABQ33788845-509F20E0-E659-4FA5-B5D3-C41AE912A88CQ33902853-1ACF8B15-2FE8-4022-A992-46554BB8AA6EQ34046796-6CB7B672-E587-4C38-ADFB-D945EE71A4EFQ34534749-C443665F-105C-4D39-8807-8B379C5D45B7Q34549629-93A99503-DE63-4E0D-8B5E-7AA2D9D308F9Q36460656-B59E0B76-F95E-4B35-9E0E-B08CB2C6F529Q37194210-6E9DC410-FD3F-42C6-B5C2-0E10FDBDB10CQ37420064-F5875319-859F-4D6F-B065-BD30C884A8B5Q37596291-084E5F78-2239-4044-B801-568E59A64385Q37717503-B651A250-0244-4BDE-A15B-3BFE4286A372Q38040304-33C0DAFF-73DA-4668-BCA2-C790DB072B76Q38239137-93562C6A-A6D9-424C-9353-0C489B649599Q39362145-B00BB59F-1232-406F-8CDA-E631D28C45E5Q41831013-B6ED7F06-2A8F-4C9A-875E-4DB58AA54522Q42123813-13D8F81C-7BCE-4BDD-B6F9-F808FA9DCE34Q46123559-B25F7FDF-991D-4124-8A65-3A7BDD8D9667Q47150655-C5A1362C-C1EF-46FF-B292-559E6FD574B8Q52560413-BE9E5D36-CAF6-437E-AD8C-E97112F78002Q53128619-EBF9BFE4-A9D5-41B4-9E42-85B0F7540D4C
P2860
Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency
description
im November 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 November 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2011
@uk
name
Increased dosage of tumor supp ...... t affecting their pluripotency
@en
Increased dosage of tumor supp ...... t affecting their pluripotency
@nl
type
label
Increased dosage of tumor supp ...... t affecting their pluripotency
@en
Increased dosage of tumor supp ...... t affecting their pluripotency
@nl
prefLabel
Increased dosage of tumor supp ...... t affecting their pluripotency
@en
Increased dosage of tumor supp ...... t affecting their pluripotency
@nl
P2093
P2860
P50
P1433
P1476
Increased dosage of tumor supp ...... t affecting their pluripotency
@en
P2093
Adriana Sanchez
Aida Herreria
Iago Maceda
Ida Paramonov
Juan C I Belmonte
Laura B Morera
Sergio Menendez
Suzanne Camus
P2860
P356
10.1111/J.1474-9726.2011.00754.X
P577
2011-11-10T00:00:00Z